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Abstract
Purpose: Little has been reported from population-based surveys on the characteristics of 
transgender persons living with HIV. Using Medical Monitoring Project (MMP) data, we describe 
the characteristics of HIV-infected transgender women and examine their care and treatment 
needs.
Methods: We used combined data from the 2009 to 2011 cycles of MMP, an HIV surveillance 
system designed to produce nationally representative estimates of the characteristics of HIV-
infected adults receiving medical care in the United States, to compare demographic, behavioral, 
and clinical characteristics, and met and unmet needs for supportive services of transgender 
women with those of non-transgender persons using Rao-Scott chi-square tests.
Results: An estimated 1.3% of HIV-infected persons receiving care in the United States self-
identified as transgender women. Transgender women were socioeconomically more marginalized 
than non-transgender men and women. We found no differences between transgender women and 
non-transgender men and women in the percentages prescribed antiretroviral therapy (ART). 
However, a significantly lower percentage of transgender women compared to non-transgender 
men had 100% ART dose adherence (78.4% versus 87.4%) and durable viral suppression (50.8% 
versus 61.4%). Higher percentages of transgender women needed supportive services. No 
differences were observed in receipt of most of supportive services, but transgender women had 
higher unmet needs than non-transgender men for basic services such as food and housing.
Conclusion: We found little difference between transgender women and non-transgender 
persons in regards to receipt of care, treatment, and most of supportive services. However, the 
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noted disparities in durable viral suppression and unmet needs for basic services should be 
explored further.
Keywords
HIV; Medical Monitoring Project; transgender women
Introduction
Transgender persons are at high risk for HIV infection. According to one systematic review, 
the prevalence of HIV among transgender women was 27.7% based on four US studies in 
which the diagnosis was established using HIV testing.1 Another systematic review that 
included international studies found that the pooled HIV prevalence was 19.1% in 
transgender women worldwide and their odds of HIV infection compared with all adults of 
reproductive age was 48.8.2 Despite the concern that transgender women living with HIV 
may not engage in or adhere to HIV care and treatment due to stigma and discrimination or 
concerns about interaction between antiretroviral therapy (ART) and hormone therapy,3-5 
Yehia and colleagues6 found that rates of retention in care, ART prescription and HIV 
suppression among transgender persons living with HIV were not significantly different 
from their non-transgender counterparts in a retrospective cohort study of HIV-infected 
adults who initiated care at 13 HIV clinics in the HIV Research Network between 2001 and 
2011.
Little has been reported on the characteristics of transgender persons living with HIV from 
population-based surveys. The Medical Monitoring Project (MMP) is a cross-sectional, 
population-based surveillance system that assesses clinical and behavioral characteristics 
among adults with HIV infection receiving outpatient medical care in the United States and 
Puerto Rico.7,8 Using data from MMP, we provide nationally representative estimates of the 
characteristics of HIV-infected transgender women (male-to-female transgender persons) in 
care and examine whether the findings from Yehia et al can be replicated in a population-
based survey to better inform us of the care and treatment needs of transgender women.
Methods
We analyzed combined data from the 2009, 2010, and 2011 data collection cycles of MMP. 
For all data collection cycles, 16 U.S. states and one territory were sampled (California, 
Delaware, Florida, Georgia, Illinois, Indiana, Michigan, Mississippi, New Jersey, New York, 
North Carolina, Oregon, Pennsylvania, Puerto Rico, Texas, Virginia, and Washington). Data 
were collected on adults aged 18 years or older receiving at least one HIV-related medical 
care visit in participating facilities between January and April of each data collection cycle 
year. Data were collected through face-to-face interviews and medical record abstractions 
from June 2009 to May 2012. The data were weighted for probability of selection and 
nonresponse to be representative of adults receiving outpatient medical care for HIV 
infection in the United States and Puerto Rico. Prevalence estimates are presented as 
weighted percentages. The reference period is the 12 months before the patient interview 
unless otherwise noted. The entire sample includes information on 13,194 participants, who, 
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after weighting for probability of selection and non-response, are estimated to represent an 
average population of 447,421 HIV-infected adults receiving medical care in the United 
States between January and April in 2009, 2010, and 2011. MMP methods are described in 
detail elsewhere.7,8
In accordance with the Code of Federal Regulations Title 45 Part 46 Subsections 46.101c 
and 46.102d9 and the Guidelines for Distinguishing Public Health Research and Public 
Health Nonresearch,10 MMP was determined by the Centers for Disease Control and 
Prevention (CDC) to be a non-research, public health surveillance activity. However, some 
participating sites obtained local Institutional Review Board (IRB) approval to conduct 
MMP as required locally.
In a face-to-face interview, respondents were asked to report their sex at birth and their 
current self-identified gender. Those who self-identified as transgender or had discordant sex 
at birth and gender were categorized as transgender. Persons whose sex at birth and current 
gender was male were categorized as non-transgender men and persons whose sex at birth 
and current gender was female were categorized as non-transgender women. Transgender 
persons were further categorized into transgender women (male-to-female transgender, i.e., 
sex at birth equals male and current gender equals transgender or female) and transgender 
men (female-to-male transgender, i.e., sex at birth equals female and current gender equals 
transgender or male). Five persons were excluded because information was missing to 
classify into one of the above categories. Further, because the number of transgender men 
was too small (n=22) to conduct comparative analyses, we focused on transgender women 
and compared their demographic, behavioral, and clinical characteristics, as well as needs 
for and met/unmet needs for supportive services with those of non-transgender men and 
non-transgender women (analytic sample size = 13,167) using Rao-Scott chi-square tests.11 
Statistical significance was defined at an alpha level of 0.05.
Results
In all, 1.3%, or an estimated 5,729 HIV-infected adults receiving medical care in the United 
States, self-identified as transgender women. Table 1 shows the demographic, behavioral, 
and clinical characteristics of transgender women compared to non-transgender men and 
non-transgender women. Mean age among transgender women was 41.9 years (median 42.9 
years). More than 80% of transgender women were of non-white race/ethnicity and had an 
annual income less than $20,000. Moreover, more than 20% of transgender women reported 
homelessness and over 30% did not have any health insurance. About one-third of 
transgender women reported injection or non-injection drug use, less than 50% reported 
being sexually active, and 17.5% reported having condomless vaginal or anal sex with an 
HIV-negative or unknown status partner. More than 90% were prescribed ART in the past 12 
months, more than three-quarters reported 100% adherence to all ART doses in the past 3 
days, and almost 70% had a suppressed viral load (defined as undetectable or <200 
copies/ml) at the most recent test, but only about half had a suppressed viral load at all tests 
during the past year (i.e., durable viral suppression). Almost one-third was screened for 
gonorrhea and chlamydia respectively, and almost two-thirds were screened for syphilis.
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Compared to both non-transgender men and women, significantly higher percentages of 
transgender women had incomes less $20,000 per year, were homeless, and did not have 
health insurance. Compared to non-transgender men, a significantly higher percentage of 
transgender women were of non-white race/ethnicity, had less than a high school education, 
and had income at or below the poverty level. Compared to non-transgender women, a 
significantly lower percentage of transgender women were of black or African-American 
race/ethnicity and a higher percentage were Hispanic or Latino.
Compared to non-transgender women, a significantly higher percentage of transgender 
women reported use of non-injection and injection drugs in the past 12 months. A 
significantly lower percentage of transgender women reported any sexual activity compared 
to non-transgender men and women, but no significant differences in the percentage 
engaging in any condomless sex or condomless sex with an HIV-negative or unknown status 
partner were noted.
Also no significant differences were observed in time since HIV diagnosis, stage of disease, 
geometric mean CD4+ T-lymphocyte cell (CD4) count in the past year between transgender 
women and non-transgender men and women. Moreover, no significant differences were 
observed between the percentages of transgender women and non-transgender men and 
women who were prescribed ART and the percentages who achieved viral suppression at 
their most recent viral load test. However, compared to non-transgender men, a significantly 
lower percentage of transgender women reported 100% adherence to all ART doses in the 
past 3 days. Also, a significantly lower percentage of transgender women, compared to non-
transgender men had a suppressed viral load on all viral load tests in the past year (i.e., 
durable viral load suppression). There were no significant differences in the percentages of 
transgender women compared to non-transgender men and women receiving gonorrhea and 
chlamydia testing, but a significantly higher percentage of transgender women than non-
transgender women were tested for syphilis. No significant differences were observed in use 
of emergency room or urgent care and hospital admission between transgender women and 
non-transgender persons.
Figure 1 compares the percentages of transgender women versus non-transgender men and 
women who needed supportive services, whose supportive service needs were met, and 
whose supportive service needs were unmet (Supplemental Table 1). Significantly higher 
percentages of transgender women, compared to non-transgender men (p<0.05), needed 
services including HIV case management (70.9% vs. 60.7%), ART adherence support 
(28.3% vs. 20.0%), HIV prevention counseling (50.1% vs. 38.9%), mental health services 
(45.5% vs. 31.8%), meal services (45.8% vs. 33.0%), domestic violence services (3.7% vs. 
1.6%), transportation services (48.2% vs. 29.8%), and housing services (40.0% vs. 21.7%). 
Compared to non-transgender women (p<0.05), transgender women had significantly higher 
percentages needing medicine through the AIDS Drug Assistance Program [ADAP] (50.7% 
vs. 39.6%) and needing housing services (40.0% vs. 30.0%). No differences were observed 
in percentages of those whose needs were unmet for most supportive services examined. 
However, significantly higher percentages of transgender women than non-transgender men 
(p<0.01) had unmet needs for meal services (13.3% vs. 6.7%) and housing services (13.4% 
vs. 7.3%).
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Discussion:
In a nationally representative sample of HIV-infected persons receiving medical care, an 
estimated 1.3% self-identified as transgender women. Transgender women in care were 
socioeconomically more marginalized than non-transgender men and women; higher 
percentages of transgender women had lower income, were homeless, and did not have 
health insurance. Similar to findings by Yehia et al.,6 a similar percentage of transgender 
women compared to non-transgender persons were prescribed ART and achieved viral 
suppression at their most recent viral load test. However, similar to findings by Sevelius et 
al.,3 a lower percentage of transgender women compared to non-transgender men reported 
adherence to ART regimen, and the equity in ART prescription was not translated into 
equity in durable viral suppression, the treatment outcome that uses more stringent criteria 
(i.e., achieving viral suppression in all tests). These findings suggest a need to investigate 
what happens to transgender women after they are prescribed ART to better understand what 
might interfere with their medication adherence and long-term viral suppression. One 
possibility is a residual need for supportive services given that transgender women are more 
likely to be socioeconomically marginalized. We found that higher percentages of 
transgender women needed supportive services. Although we observed little difference 
between transgender women and non-transgender persons in regards to receipt of most 
supportive services, a higher percentage of transgender women compared to non-transgender 
men had unmet needs for basic services such as meal and housing. These unmet basic needs 
could interfere with medication adherence behaviors12,13 that might have resulted in the 
observed disparities in treatment outcomes. Future research might explore the associations 
among these factors to explain the disparities between transgender and non-transgender 
persons, which could further inform programs aiming to reduce such disparities
Limitations of our study are as follows. MMP collects data from HIV-infected persons 
receiving medical care, and just like Yehia et al., our findings cannot be generalized to all 
persons living with HIV. To the extent that transgender HIV-infected persons avoid accessing 
healthcare due to stigma and past negative experiences,5 there may be significant disparities 
in how they access HIV care in the first place. We also did not have data on specific needs of 
transgender women such as hormone therapy and other transgender-specific health care 
services, thus our findings on met and unmet needs for supportive services need to be 
interpreted with caution. Finally, relative to transgender women very little is known in the 
field of HIV prevention about HIV risk and needs of transgender men (female-to-male 
transgender persons).14 Yet, we were not able to investigate the unique characteristics and 
needs of transgender men due to small sample size.
Conclusion:
We found few differences between HIV-infected transgender women and non-transgender 
persons in care with respect to receipt of most care, treatment, and supportive services; 
however, the noted disparities in durable viral suppression and unmet needs for basic 
services should be explored further. Because MMP is conducted annually, CDC will monitor 
progress towards the goal of reducing health disparities among transgender persons living 
with HIV.
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Figure 1. 
Comparison of met and unmet supportive service needs among HIV-infected transgender 
women (green bars), non-transgender men (blue bars), and non-transgender women (red 
bars), Medical Monitoring Project, United States, 2009-2011
Abbreviations: ADAP=AIDS Drug Assistance Program
Met supportive service need defined as needing and receiving service. Unmet supportive 
service need defined as needing, but not receiving service.
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